Affinity Asset Advisors »

Rapt Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $1.9M 620k 3.05
2024-03-31 $5.7M 637k 8.98

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Rapt Therapeutics

Vanguard Group
Column Group
BlackRock
Kingdon Capital Management
Morgan Stanley
Millennium Management
Deutsche Bank Aktiengesellschaft
D. E. Shaw & Co
Federated Investors
Point72 Asset Management
Two Sigma Advisers
Geode Capital Management
State Street Corporation
Euclidean Capital
Affinity Asset Advisors

View all funds holding Rapt Therapeutics